BioCentury
ARTICLE | Strategy

Biomira modifies its aspirations

May 12, 1997 7:00 AM UTC

Presented with the opportunity to tie up with Chiron Corp.'s oncology business, Biomira Inc. chose to put on hold its own long-range plans for marketing a comprehensive cancer management package.

The companies last week announced a deal that will position BIOMF's Theratope cancer vaccine to be sold in the U.S. and Europe with CHIR's ProLeukin and Aredia cancer therapies, drugs that made up the bulk of CHIR's $183 million therapeutics business in 1996...